Pediatrics,

Bronchiolitis Management in 2026: What Still Works (and What Doesn’t)

By Jen Janocha, PA-C on

November 03, 2026

Jen Janocha, PA-C, completed an Ambulatory Pediatric Fellowship with Carolinas Healthcare and has spent the past decade caring for children in western New York. She also serves as a Clinical Manager at Hippo Education.

Every fall, the wheezy, snotty, tachypneic infants arrive right on schedule. With them comes a familiar urge to do something. In acute bronchiolitis, though, our most powerful clinical skill is often knowing what not to do. And sometimes the hardest prescription to write is the one you don't.

High-quality international evidence keeps landing on the same simple truth: bronchiolitis management is fundamentally supportive. The AAP guideline is now more than a decade old, but newer trials have only reinforced its core message.

Here's a practical, evidence-based guide to diagnosing and managing bronchiolitis in children under 24 months, built around the questions that actually come up on a busy winter shift.

Put Down the X-ray Order: Diagnosis is Clinical

Bronchiolitis is a clinical diagnosis. A previously healthy infant with a viral prodrome, then increased work of breathing with diffuse wheezes or crackles, rarely needs a workup.

Routine viral swabs. An in-office panel can confirm RSV, but a positive result rarely changes management or outcomes in a well-appearing infant. Testing can still be useful for inpatient cohorting or when the result would genuinely change a decision.
Routine chest radiographs. The AAP explicitly recommends against them. Patchy atelectasis in viral bronchiolitis is easily mistaken for bacterial consolidation, which drives unnecessary antibiotics. Save imaging for atypical presentations, marked asymmetry on exam, or concern for impending respiratory failure.
The febrile young infant. Clinical bronchiolitis, even without a positive RSV swab, makes invasive bacterial infections like bacteremia or meningitis much less likely. The risk is so low that standard fever protocols actually exclude well-appearing, full-term (≥37 weeks) infants aged 8–60 days from fever workup protocols if they have clinical bronchiolitis.

The Cheat Sheet: What Works vs What Doesn’t

Major clinical practice guidelines, including the AAP, NICE, and Australian consensus panels, agree that non-invasive supportive care is the standard of care.

Recommended (Do)	Not Recommended (Don't)
-Superficial nasal suctioning -Hydration support (oral, nasogastric, or isotonic IV) -Oxygen for persistent hypoxemia (AAP <90%, NICE <92%) -High-flow nasal cannula (HFNC) as rescue for failing standard oxygen -Minimal handling -Intermittent pulse oximetry in stable infants	-Deep nasopharyngeal suctioning -Bronchodilators (albuterol) -Epinephrine -Corticosteroids (inhaled or systemic) -Antibiotics (without a documented bacterial infection) -Chest physiotherapy -Ribavirin (except select immunocompromised children)

The Usual Suspects (and Why They Don’t Work)

Bronchodilators (β2-agonists). Bronchiolitis is driven by mucosal edema, epithelial sloughing, and mucus plugging, not smooth muscle bronchospasm. Trials show no consistent benefit on resolution, admission rates, or length of stay. The AAP's 2014 clinical practice guideline on bronchiolitis does not recommend even a trial dose.

What about trends in practice? For the typical toddler with first-time viral bronchiolitis, albuterol is not indicated. However, clinicians often perform a closely monitored, one-time trial — particularly when atypical features suggest an underlying asthmatic or atopic phenotype. While standard practice remains to withhold albuterol, an individualized trial may be justified in these high-risk scenarios.

Corticosteroids (inhaled or systemic). Large randomized trials show no change in clinical course or hospitalization rates.
Epinephrine. Not recommended for routine inpatient or outpatient use. Nebulized epinephrine may briefly improve symptom scores in the ED, but it doesn't change disease progression or admission rates.
Antibiotics. Ineffective for the viral illness. Reserve them for a documented co-existing bacterial infection, such as acute otitis media or UTI.
Chest physiotherapy. Manual or mechanical chest PT doesn't lower oxygen requirements, improve severity scores, or shorten hospital stays.
Ribavirin. Not recommended for routine use because of limited efficacy, significant drug toxicity, high cost, and operational complexity. It's reserved for select severely immunocompromised children.

The Core Pillars of Supportive Care

Superficial nasal suctioning: Gentle bulb or nasal aspiration with saline before feeds and sleep gives real symptomatic relief. Avoid routine deep nasopharyngeal suctioning, which has been associated with longer hospital stays and can traumatize already swollen mucosa.

Hydration and feeding: Tachypnea and congestion make feeding exhausting. Encourage smaller, more frequent feeds. If respiratory distress compromises feeding or increases aspiration risk, switch to nasogastric (NG) feeding or intravenous (IV) hydration. If you go IV, use isotonic fluids, since these infants are at risk for hyponatremia.

Targeted oxygen therapy: The AAP supports withholding oxygen when SpO2 stays at or above 90% in a previously healthy infant. NICE uses a threshold of 92%. Brief, self-resolving desaturations are common and don't require intervention.

Pulse oximetry, less is more: Continuous monitoring in a stable infant can catch harmless dips, prolong oxygen use and delay discharge. The AAP allows clinicians to forgo continuous pulse oximetry in infants who are improving or off oxygen.

Minimal handling: Agitation raises metabolic demand and oxygen consumption. Clustering care and letting the baby rest is a legitimate therapeutic intervention.

High-Flow Nasal Cannula (HFNC): Great Rescue, Not a Default

HFNC has become a winter staple, and the evidence supports a targeted role rather than routine use. In a large multicenter trial, hypoxemic infants on the ward who started HFNC early needed escalation of care less often than those on standard oxygen (12% vs. 23%). However, ICU admission rates were not meaningfully different.

The practical takeaway: many infants who fail standard low-flow oxygen respond well to rescue HFNC. Start with standard oxygen, and escalate to high-flow when an infant is failing it, rather than putting every hypoxemic baby on HFNC from the start. Check your local protocols, since where HFNC can be used (ward vs. ICU) varies by institution.

The Salty Gray Zone: Nebulized Hypertonic Saline (3%)

This is where guidelines truly diverge. Older trials suggested modest reductions in length of stay when hospitalizations lasted longer than 72 hours, but newer, larger trials haven't confirmed that benefit. The AAP allows it for hospitalized infants, while other guidelines advise against it. Where everyone agrees: hypertonic saline is not recommended in the emergency department or outpatient setting.

Who to Worry About

Most infants with bronchiolitis do fine at home. Your job is to spot the ones who won't.

Higher risk for severe disease:

Age under 3 months
Prematurity, especially under 32 weeks' gestation
Chronic lung disease, including bronchopulmonary dysplasia
Hemodynamically significant congenital heart disease
Neuromuscular disease
Immunodeficiency

Red Flags - adopted from NICE

Urgent escalation of care	Consider admission
-Apnea, observed or reported -Central cyanosis -Severe distress: grunting, marked retractions, RR over 70 -Persistent SpO2 under 92% on room air -Infant looks seriously unwell	-Respiratory rate over 60 -Oral intake <50–75% of usual over 24 hours -Clinical signs of dehydration -Higher-risk infant (list above) with worsening symptoms -Social concerns, distance from care, or caregiver unable to manage at home

Also remember the clock: symptoms usually peak around days 3 to 5, so a day-2 infant who looks borderline may get worse before getting better. Consider that when deciding on discharge and follow-up timing.

Talking to Parents: “Doing Nothing” Is Actually Doing a Lot

Parents often arrive expecting a prescription. Framing the plan as active supportive care, rather than "there's nothing we can do," sets expectations and builds trust.

Set the timeline. Symptoms usually peak around days 3 to 5 and improve over 1 to 2 weeks. The cough can linger for 3 to 4 weeks. Saying this up front prevents a lot of "it's still not gone" return visits.

Reframe the prescription. Inhalers, steroids, and antibiotics can't open airways narrowed by viral mucus and swelling. Skipping them spares the baby side effects without giving up any benefit.

Give them a job. Focus on what parents can do at home:

Saline drops and gentle nasal suction before feeds and sleep
Smaller, more frequent feeds
Tracking wet diapers to monitor hydration
Avoiding over-the-counter cough and cold medicines
Keeping the baby away from tobacco smoke and vaping

Be specific about return precautions. Tell parents to come back right away for pauses in breathing, blue or gray color around the lips, grunting, ribs pulling in with each breath, a baby too tired to feed, or significantly fewer wet diapers.

References

Elliott SA, et al. Comparative efficacy of bronchiolitis interventions in acute care: A network meta-analysis. Pediatrics. 2021;147(5):e2020040816. PMID: 33893229
Franklin D, et al. A randomized trial of high-flow oxygen therapy in infants with bronchiolitis. N Engl J Med. 2018;378(12):1121-1131. PMID: 29562151
Mellick L, et al. Outpatient medications deimplemented by the AAP Bronchiolitis Guidelines: An umbrella review of meta-analyses. Pediatr Pulmonol. 2025;60(1):e27391. PMID: 39601617
Mussman GM, Parker MW, Statile A, Sucharew H, Brady PW. Suctioning and length of stay in infants hospitalized with bronchiolitis. JAMA Pediatr. 2013;167(5):414-421. PMID: 23460088
National Institute for Health and Care Excellence. 2019 surveillance of bronchiolitis in children: diagnosis and management (NICE Guideline NG9). August 27, 2019. PMID: 34464039
Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014;134(5):e1474-e1502. PMID: 25349312
Rodríguez-Martínez CE, Midulla F, Nino G. Viral bronchiolitis in infants in the era of targeted therapies: What now and what's next?. Pediatr Pulmonol. 2025;60(7):e71215. PMID: 40704578
Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP. Nebulised hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syst Rev. 2013;(7):CD006458. Published 2013 Jul 31. PMID: 23900970